Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Sulopenem

Generic Name: Sulopenem

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₅NO_₅S_₃

CAS Number: 120788-07-0

Unique Ingredient Identifier: XX514BJ1XW

Overview

Sulopenem is under investigation in clinical trial NCT03357614 (Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults).

Background

Sulopenem is under investigation in clinical trial NCT03357614 (Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women

Phase 3

Completed

Posted: 2022/10/18

Sponsor:Iterum Therapeutics,...

ID:NCT05584657

Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

Phase 1

Withdrawn

Posted: 2021/01/08

Sponsor:Iterum Therapeutics,...

ID:NCT04700787

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

Posted: 2020/12/24

Sponsor:Iterum Therapeutics,...

ID:NCT04682834

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

Phase 3

Completed

Posted: 2017/11/30

Sponsor:Iterum Therapeutics,...

ID:NCT03357614

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Phase 3

Completed

Posted: 2017/11/30

Sponsor:Iterum Therapeutics,...

ID:NCT03358576

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Iterum Therapeutics Secures $5 Million in Funding to Advance Commercialization of Novel Antibiotic ORLYNVAH

24 days ago

Iterum Therapeutics has closed a $5 million registered direct offering of ordinary shares to support pre-commercialization activities for ORLYNVAH, its FDA-approved oral antibiotic for uncomplicated urinary tract infections.

FDA Approves Blujepa: First Novel Oral Antibiotic for UTIs in Over Two Decades

2 months ago

The FDA has approved gepotidacin (Blujepa), the first new class of oral antibiotics for urinary tract infections in nearly 30 years, addressing growing concerns about antimicrobial resistance.

FDA Approves Blujepa, First New Class of Oral Antibiotic for UTIs in Nearly 30 Years

2 months ago

GSK's Blujepa (gepotidacin) has received FDA approval for treating uncomplicated urinary tract infections, marking the first new class of oral antibiotics for UTIs in nearly three decades.

FDA Approves ORLYNVAH™: First New Oral Treatment for Uncomplicated UTIs in 25 Years

3 months ago

Iterum Therapeutics receives FDA approval for ORLYNVAH™, marking the first branded uncomplicated UTI treatment to enter the U.S. market in over 25 years and the first oral penem antibiotic approved in the country.

Iterum Therapeutics Achieves FDA Approval for Orlynvah in Treating UTIs

5 months ago

Iterum Therapeutics has reached a significant milestone with the FDA approval of Orlynvah, a treatment for uncomplicated urinary tract infections in adult women, marking its first approved indication and introducing the first oral penem in the U.S.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy